The New Insulins are Coming: What Does This Mean to the Practicing Clinician?
Live online June 14, 2016
(Sessions 1 and 2) and
August 4, 2016
(Sessions 3 and 4), and available on demand through February 4, 2017
Posted by...Bernard Sklar, MD.
Free Diabetes CME Credit hours...1.0.
CME Credits Awarded by....Primary Care Network.
Instruction Type...Streaming Video Lecture and discussion.
Target Audiences...This program is intended for US-based primary care providers, clinical endocrinologists/diabetologists, nephrologists, cardiologists, emergency department specialists, pharmacists, and other clinicians caring for patients with type 2 diabetes.
Educational material updated...June 14, 2016
Expiration of CME credit...February 4, 2017
Financial Support...Novo Nordisk.
At the conclusion of the 4 sessions of The New Insulins are
, you will be able to:
• Identify T2DM patients who would benefit from insulin-based therapy
• Discuss strategies to overcome patient and clinician barriers to the successful initiation of insulin therapy
• Differentiate how new and emerging insulin products, including new entities and new modes of administration, differ from previously available insulin products with respect to pharmacokinetic and pharmacodynamic features
• Apply key, clinically relevant data derived from pivotal trials of new and emerging insulin products
• Identify the potential place in therapy for new insulins, including how these indications compare to those of the previously available insulins
• Explain the similarities and differences between a follow-on (biosimilar) insulin and a reference insulin
• Delineate methods for initiating and titrating new insulin products
• Explore the potential role for new insulins in helping patients meet diabetes management goals while minimizing adverse effects associated with insulin regimens
• Apply learnings from previous activities to advance management of your patients using new insulin products
• Develop insulin regimens that are based on the product's pharmacodynamic properties and are tailored to the glycemic control needs of the patient